Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Mosunetuzumab
Non-Hodgkin Lymphoma
Bristol-Myers Squibb
P3
BB
(68)
Nivolumab
Brain Neoplasm
InSightec
P3
BB
(68)
Nivolumab
Cutaneous Melanoma
Fred Hutchinson Cancer Center
P3
BB
(68)
Nivolumab
Clinical Stage IV Cutaneous Melanoma AJCC v8
Fred Hutchinson Cancer Center
P3
BB
(68)
Nivolumab
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)
P3
BB
(68)
Nivolumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in Oncology
P3
BB
(68)
Obinutuzumab
Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(68)
PANITUMUMAB
Colorectal Cancer
MSPU des 3 Provinces
P3
BB
(68)
Pembrolizumab
Hepatocellular Carcinoma
Fudan University
P3
BB
(68)
Pembrolizumab
Metastatic Bladder Urothelial Carcinoma
Fred Hutchinson Cancer Center
P3
BB
(68)
Pembrolizumab
Recurrent Primary Peritoneal Carcinoma
Roswell Park Cancer Institute
P3
BB
(68)
Serplulimab
Non Small Cell Lung Cancer
Tang-Du Hospital
P3
BB
(68)
Serplulimab
Small Cell Lung Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P3
BB
(68)
TRASTUZUMAB
Breast Disorder
Incepta Pharmaceuticals Ltd
P3
BB
(68)
TRASTUZUMAB
Breast Neoplasm
Merck Sharp & Dohme LLC
P3
BB
(68)
TRASTUZUMAB
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(68)
TRASTUZUMAB
Invasive Breast Carcinoma
Massachusetts General Hospital
P3
BB
(68)
TRASTUZUMAB
Stage III Colon Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(68)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Recurrent Rectal Carcinoma
SWOG Cancer Research Network
P2
BB
(68)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Angioimmunoblastic T-Cell Lymphoma
Ou Bai, MD/PHD
P2
BB
(68)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
HIV Infectious Disease
City of Hope Medical Center
P2
BB
(68)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Lymphoma, T-Cell
Memorial Sloan Kettering Cancer Center
P2
BB
(68)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Malignant Pancreatic Neoplasm
Baki Topal
P2
BB
(68)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Plasma Cell Myeloma
Sanofi
P2
BB
(68)
Ipilimumab
Recurrent Hodgkin Lymphoma
Dana-Farber Cancer Institute
P2
BB
(68)
Showing 151 to 175 of 6,371 assets
Previous
Page 7 of 255
Next